Panbela Therapeutics, Inc. (NASDAQ:PBLA – Get Free Report)’s share price shot up 2.4% during trading on Tuesday . The stock traded as high as $0.34 and last traded at $0.34. 5,495 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 238,504 shares. The stock had previously closed at $0.34.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “neutral” rating on shares of Panbela Therapeutics in a research note on Thursday, August 15th.
Check Out Our Latest Stock Report on PBLA
Panbela Therapeutics Stock Performance
Panbela Therapeutics (NASDAQ:PBLA – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($1.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.07) by $0.60.
About Panbela Therapeutics
Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.
Further Reading
- Five stocks we like better than Panbela Therapeutics
- Breakout Stocks: What They Are and How to Identify Them
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Top Biotech Stocks: Exploring Innovation Opportunities
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- What Does a Stock Split Mean?
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.